RT Journal Article
SR Electronic
T1 Health-related utility values of patients with primary Sjögren's syndrome and its predictors
JF Annals of the Rheumatic Diseases
JO Ann Rheum Dis
FD BMJ Publishing Group Ltd and European League Against Rheumatism
SP 1362
OP 1368
DO 10.1136/annrheumdis-2012-202863
VO 73
IS 7
A1 Lendrem, Dennis
A1 Mitchell, Sheryl
A1 McMeekin, Peter
A1 Bowman, Simon
A1 Price, Elizabeth
A1 Pease, Colin T
A1 Emery, Paul
A1 Andrews, Jacqueline
A1 Lanyon, Peter
A1 Hunter, John
A1 Gupta, Monica
A1 Bombardieri, Michele
A1 Sutcliffe, Nurhan
A1 Pitzalis, Costantino
A1 McLaren, John
A1 Cooper, Annie
A1 Regan, Marian
A1 Giles, Ian
A1 Isenberg, David
A1 Vadivelu, Saravanan
A1 Coady, David
A1 Dasgupta, Bhaskar
A1 McHugh, Neil
A1 Young-Min, Steven
A1 Moots, Robert
A1 Gendi, Nagui
A1 Akil, Mohammed
A1 Griffiths, Bridget
A1 Ng, Wan-Fai
A1 on behalf of the UK primary Sjögren's Syndrome Registry
YR 2014
UL http://ard.bmj.com/content/73/7/1362.abstract
AB Objectives EuroQoL-5 dimension (EQ-5D) is a standardised preference-based tool for measurement of health-related quality of life and EQ-5D utility values can be converted to quality-adjusted life years (QALYs) to aid cost-utility analysis. This study aimed to evaluate the EQ-5D utility values of 639 patients with primary Sjögren's syndrome (PSS) in the UK. Methods Prospective data collected using a standardised pro forma were compared with UK normative data. Relationships between utility values and the clinical and laboratory features of PSS were explored. Results The proportion of patients with PSS reporting any problem in mobility, self-care, usual activities, pain/discomfort and anxiety/depression were 42.2%, 16.7%, 56.6%, 80.6% and 49.4%, respectively, compared with 5.4%, 1.6%, 7.9%, 30.2% and 15.7% for the UK general population. The median EQ-5D utility value was 0.691 (IQR 0.587–0.796, range −0.239 to 1.000) with a bimodal distribution. Bivariate correlation analysis revealed significant correlations between EQ-5D utility values and many clinical features of PSS, but most strongly with pain, depression and fatigue (R values>0.5). After adjusting for age and sex differences, multiple regression analysis identified pain and depression as the two most important predictors of EQ-5D utility values, accounting for 48% of the variability. Anxiety, fatigue and body mass index were other statistically significant predictors, but they accounted for <5% in variability. Conclusions This is the first report on the EQ-5D utility values of patients with PSS. These patients have significantly impaired utility values compared with the UK general population. EQ-5D utility values are significantly related to pain and depression scores in PSS.